Pregnancy in kidney transplantation: Past and present experience : Pregnancy after transplantationBERERHI, L; BEDROSSIAN, J; METIVIER, F et al.Transplantation proceedings. 1997, Vol 29, Num 5, issn 0041-1345, p. 2478Conference Paper

Exploration scintigraphique du greffon rénal = Scintigraphy of renal transplantRAMACKERS, J. M; MARRAST, A. C; TOURAINE, J. L et al.Médecine nucléaire (Paris). 1995, Vol 19, Num 5-6, pp 367-375, issn 0928-1258Article

La transplantation rénale = Kydeney transplantationMARRAST, A. C; RAMACKERS, J. M; PEYRIN, J. O et al.Médecine nucléaire (Paris). 1995, Vol 19, Num 5-6, pp 361-366, issn 0928-1258Article

Management of ovarian cancer in the renal transplant recipient with cyclophosphamide used as an immunosuppressive and antineoplastic agentVINCENT, F; MICHEL, M; MARRAST, A. C et al.Transplantation proceedings. 1995, Vol 27, Num 4, issn 0041-1345, p. 2432Conference Paper

Hyperoxalurie primitive de type 1: le dilemme thérapeutique = Type I primary hyperoxaluria: treatment dilemmaCOCHAT, P; DELORAINE, A; OLIVE, F et al.Actualités néphrologiques Jean Hamburger. 1994, pp 231-246, issn 1168-1098Article

Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic®)BUDDE, K; KNOLL, G; CURTIS, J et al.Clinical nephrology. 2006, Vol 66, Num 2, pp 103-111, issn 0301-0430, 9 p.Article

Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic®) is safe in kidney transplant patientsSALVADORI, M; HOLZER, H; CIVATI, G et al.Clinical nephrology. 2006, Vol 66, Num 2, pp 112-119, issn 0301-0430, 8 p.Article